LivaNova/$LIVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LivaNova
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Ticker
$LIVN
Sector
Primary listing
Employees
2,900
Headquarters
Website
LivaNova Metrics
BasicAdvanced
$3B
-
-$3.89
0.93
-
Price and volume
Market cap
$3B
Beta
0.93
52-week high
$58.91
52-week low
$32.48
Average daily volume
689K
Financial strength
Current ratio
1.289
Quick ratio
0.984
Long term debt to equity
34.846
Total debt to equity
42.996
Interest coverage (TTM)
3.43%
Profitability
EBITDA (TTM)
246.523
Gross margin (TTM)
69.45%
Net profit margin (TTM)
-16.14%
Operating margin (TTM)
15.53%
Effective tax rate (TTM)
-16.49%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
5.12%
Return on equity (TTM)
-17.87%
Valuation
Price to revenue (TTM)
2.282
Price to book
2.67
Price to tangible book (TTM)
33.2
Price to free cash flow (TTM)
18.431
Free cash flow yield (TTM)
5.43%
Free cash flow per share (TTM)
2.98
Growth
Revenue change (TTM)
8.23%
Earnings per share change (TTM)
1,157.46%
3-year revenue growth (CAGR)
8.77%
3-year earnings per share growth (CAGR)
91.89%
What the Analysts think about LivaNova
Analyst ratings (Buy, Hold, Sell) for LivaNova stock.
Bulls say / Bears say
LivaNova’s second-quarter revenue grew 10.7% year-over-year to $352.5 million, surpassing analyst forecasts and prompting a 200 basis point lift in full-year revenue guidance to 8%–9% on a constant-currency basis, while adjusted EPS guidance was increased to $3.70–3.80 (Reuters).
LivaNova began commercial rollout of its Essenz™ Perfusion System in China—the company’s second-largest heart-lung machine market—following recent approval from the NMPA, positioning itself to compete in a $185,000-per-procedure market and fueling long-term cardiopulmonary growth (S&P Capital IQ).
Wall Street maintains a positive outlook, with the average 12-month price target at $58.00—26.5% above the August 5 closing price—and zero sell ratings, signaling strong analyst confidence in LivaNova’s growth prospects (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
LivaNova Financial Performance
Revenues and expenses
LivaNova Earnings Performance
Company profitability
LivaNova News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LivaNova stock?
LivaNova (LIVN) has a market cap of $3B as of September 17, 2025.
What is the P/E ratio for LivaNova stock?
The price to earnings (P/E) ratio for LivaNova (LIVN) stock is 0 as of September 17, 2025.
Does LivaNova stock pay dividends?
No, LivaNova (LIVN) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next LivaNova dividend payment date?
LivaNova (LIVN) stock does not pay dividends to its shareholders.
What is the beta indicator for LivaNova?
LivaNova (LIVN) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.